Messenger RNA-lipid nanoparticle complex (mRNA-LNP)

The Messenger RNA-lipid nanoparticle (mRNA-LNP) complex is a sophisticated drug delivery platform designed to protect fragile mRNA molecules from enzymatic degradation and facilitate their entry into target cells (Nature Reviews Drug Discovery, 2021). These complexes typically consist of four lipid components: ionizable lipids that enable endosomal escape, PEGylated lipids that enhance stability and circulation time, and structural lipids like cholesterol and phospholipids (Molecular Therapy, 2019). Upon administration, the LNP facilitates cellular uptake through endocytosis and subsequent release of the mRNA into the cytoplasm, where it utilizes the host's translational machinery to produce functional proteins (Nature Nanotechnology, 2020). This technology gained global prominence with the development of COVID-19 vaccines, such as those by Pfizer-BioNTech and Moderna, but its applications extend to cancer immunotherapy and protein replacement therapies for genetic disorders (Cell, 2022). By enabling the body to produce its own therapeutic or antigenic proteins, mRNA-LNP complexes represent a transformative approach in modern pharmacology and vaccinology (Journal of Controlled Release, 2021).

Other names

mRNA-LNPLipid nanoparticle-encapsulated mRNAmRNA-lipid complexLNP-mRNANucleoside-modified mRNA-lipid nanoparticle

The mRNA-LNP complex facilitates the delivery of messenger RNA into target cells via endocytosis (Nature Reviews Materials, 2021). Once inside the endosome, the ionizable lipids within the LNP become protonated in the acidic environment, leading to endosomal membrane destabilization and the release of mRNA into the cytosol (ACS Nano, 2017). The released mRNA is then translated by the host cell's ribosomes into a specific protein, which can serve as a vaccine antigen or a therapeutic protein replacement (Nature, 2021).